GSK announces positive topline results of Phase lll study of IPX066 in advanced Parkinson's disease
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (GSK) announced positive, top-line results of the ADVANCE-Parkinson's Disease (PD) Phase III clinical study, conducted by Impax Pharmaceuticals, of IPX066 versus immediate-release (IR) carbidopa-levodopa (CD-LD) in advanced PD patients experiencing motor fluctuations.
Amgen Donates $1 Million to Help Japanese Disaster Victims
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced that the company will donate $1 million to Japanese disaster relief efforts. Amgen and the Amgen Foundation will distribute the funds to both Direct Relief International and International Medical Corps to bring basic needs and vital health services to those affected in Japan.
Abbott Supports Relief Efforts in Japan
- Details
- Category: Abbott
Abbott (NYSE: ABT), through its philanthropic foundation the Abbott Fund, is providing $3 million (245 million yen) to support immediate relief efforts in response to the devastating earthquake and tsunami in Japan.
OncoTrack: A new International consortium launches project in the area of genomic cancer diagnostics
- Details
- Category: Bayer
OncoTrack, an international consortium of over 60 scientists, managed by Bayer HealthCare Pharmaceuticals and the Max Planck Institute for Molecular Genetics, has launched one of Europe's largest collaborative academic-industry research projects to develop and assess novel approaches for identification of new markers for colon cancer.
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta® (belimumab) for the treatment of adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) who are receiving standard therapy.
FDA accepts new drug application for investigational compound Dapagliflozin
- Details
- Category: AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced that the US Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for dapagliflozin, an investigational compound for the treatment of adults with type 2 diabetes mellitus.
Genzyme Board Unanimously Recommends that Shareholders Accept sanofi-aventis Revised Offer and Tender Shares
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) announced that its Board of Directors unanimously recommends that Genzyme shareholders accept the sanofi-aventis revised tender offer to purchase all outstanding shares of Genzyme common stock for $74.00 and one contingent value right, per share.
More Pharma News ...
- Pfizer Announces Primary Endpoints Met in Second Phase 3 Clinical Trial of Tofacitinib
- Bayer extends support to fight Chagas disease
- Breakaway From Cancer(R) Launches Newly-Enhanced Website
- Breaking the Taboo Associated with Hemorrhoidal Disease
- Nycomed well positioned in emerging markets
- Roche Annual General Meeting: dividend raised by 10%
- Nycomed's novel COPD therapy roflumilast receives FDA approval